Verastem | VSTM - Ebitda

Verastem reported $-16817000 in EBITDA for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Ebitda Change
AstraZeneca AZN:LN USD 3.32B 283M
Cytokinetics CYTK:US USD -125372000 18.34M
Gilead Sciences GILD:US USD 2.7B 662M
Immunogen IMGN:US USD -59131000 17.87M
Laboratory Of America LH:US USD 876.4M 234.8M
Novartis NOVN:VX USD 4.5B 193M
Pfizer PFE:US USD 6.94B 3.94B
Roche Holding ROG:VX 10.43B 3B
Tg Therapeutics TGTX:US USD -51989000 17.1M
Verastem VSTM:US USD -16817000 862K
YTE INCY:US USD 111.58M 23.37M
Ziopharm Oncology ZIOP:US USD -7827000 254K